Hydroxychloroquine in IgA nephropathy: a systematic review

Background Hydroxychloroquine (HCQ) has recently been reported to be a promising and safe anti-proteinuric agent for IgA nephropathy (IgAN) patients. In the present systematic review, we aimed to summarize the evidence concerning the benefits and risks of HCQ therapy in IgAN. Methods Electronic data...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gabriel Stefan, Gabriel Mircescu
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	egfr hydroxychloroquine iga nephropathy meta-analysis proteinuria systematic review Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/a21e508e22924ad9b6fa8d86af66496c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a21e508e22924ad9b6fa8d86af66496c
record_format	dspace
spelling	oai:doaj.org-article:a21e508e22924ad9b6fa8d86af66496c2021-11-17T14:21:55ZHydroxychloroquine in IgA nephropathy: a systematic review0886-022X1525-604910.1080/0886022X.2021.2000875https://doaj.org/article/a21e508e22924ad9b6fa8d86af66496c2021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/0886022X.2021.2000875https://doaj.org/toc/0886-022Xhttps://doaj.org/toc/1525-6049Background Hydroxychloroquine (HCQ) has recently been reported to be a promising and safe anti-proteinuric agent for IgA nephropathy (IgAN) patients. In the present systematic review, we aimed to summarize the evidence concerning the benefits and risks of HCQ therapy in IgAN. Methods Electronic databases were searched for randomized, cohort, or case-control studies with IgAN biopsy-proven patients comparing the effects of HCQ with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or immunosuppression on proteinuria reduction. Results Five studies, one randomized and three observational, involving a total of 504 patients, were eligible for inclusion. Overall, there was a tendency of HCQ treatment to reduce proteinuria. In the studies where the control arm was supportive therapy, HCQ significantly reduced proteinuria at 6 months. However, in the studies that compared HCQ to immunosuppressive therapy, we found no difference in proteinuria reduction. HCQ had no impact on eGFR. Conclusion HCQ seems to be an efficient alternative therapy for patients with IgAN who insufficiently respond to conventional therapy. However, ethnically diverse randomized controlled studies with long-term follow-up are needed.Gabriel StefanGabriel MircescuTaylor & Francis Grouparticleegfrhydroxychloroquineiga nephropathymeta-analysisproteinuriasystematic reviewDiseases of the genitourinary system. UrologyRC870-923ENRenal Failure, Vol 43, Iss 1, Pp 1520-1527 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	egfr hydroxychloroquine iga nephropathy meta-analysis proteinuria systematic review Diseases of the genitourinary system. Urology RC870-923
spellingShingle	egfr hydroxychloroquine iga nephropathy meta-analysis proteinuria systematic review Diseases of the genitourinary system. Urology RC870-923 Gabriel Stefan Gabriel Mircescu Hydroxychloroquine in IgA nephropathy: a systematic review
description	Background Hydroxychloroquine (HCQ) has recently been reported to be a promising and safe anti-proteinuric agent for IgA nephropathy (IgAN) patients. In the present systematic review, we aimed to summarize the evidence concerning the benefits and risks of HCQ therapy in IgAN. Methods Electronic databases were searched for randomized, cohort, or case-control studies with IgAN biopsy-proven patients comparing the effects of HCQ with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or immunosuppression on proteinuria reduction. Results Five studies, one randomized and three observational, involving a total of 504 patients, were eligible for inclusion. Overall, there was a tendency of HCQ treatment to reduce proteinuria. In the studies where the control arm was supportive therapy, HCQ significantly reduced proteinuria at 6 months. However, in the studies that compared HCQ to immunosuppressive therapy, we found no difference in proteinuria reduction. HCQ had no impact on eGFR. Conclusion HCQ seems to be an efficient alternative therapy for patients with IgAN who insufficiently respond to conventional therapy. However, ethnically diverse randomized controlled studies with long-term follow-up are needed.
format	article
author	Gabriel Stefan Gabriel Mircescu
author_facet	Gabriel Stefan Gabriel Mircescu
author_sort	Gabriel Stefan
title	Hydroxychloroquine in IgA nephropathy: a systematic review
title_short	Hydroxychloroquine in IgA nephropathy: a systematic review
title_full	Hydroxychloroquine in IgA nephropathy: a systematic review
title_fullStr	Hydroxychloroquine in IgA nephropathy: a systematic review
title_full_unstemmed	Hydroxychloroquine in IgA nephropathy: a systematic review
title_sort	hydroxychloroquine in iga nephropathy: a systematic review
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/a21e508e22924ad9b6fa8d86af66496c
work_keys_str_mv	AT gabrielstefan hydroxychloroquineiniganephropathyasystematicreview AT gabrielmircescu hydroxychloroquineiniganephropathyasystematicreview
_version_	1718425499962703872

Hydroxychloroquine in IgA nephropathy: a systematic review

Ejemplares similares